Drug Gets Breakthrough Therapy Designation for HER2-Mutant Lung Cancer

The FDA granted a breakthrough therapy designation to BAY 2927088 after it showed promise in treating patients with HER2 mutations.

Related Keywords

Dominik Ruettinger ,Drug Administration ,Head Of Research ,Early Development ,Pharmaceuticals Division ,